The estimated Net Worth of Lisa Bright is at least $4.42 Миллион dollars as of 29 October 2019. Ms. Bright owns over 595 units of Intercept Pharmaceuticals Inc stock worth over $355,908 and over the last 9 years she sold ICPT stock worth over $2,134,906. In addition, she makes $1,932,940 as President и International at Intercept Pharmaceuticals Inc.
Lisa has made over 32 trades of the Intercept Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 595 units of ICPT stock worth $44,625 on 29 October 2019.
The largest trade she's ever made was selling 5,000 units of Intercept Pharmaceuticals Inc stock on 3 December 2018 worth over $557,100. On average, Lisa trades about 394 units every 31 days since 2015. As of 29 October 2019 she still owns at least 18,732 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Ms. Bright stock trades at the bottom of the page.
Lisa Bright serves as President, International of the Company. Ms. Bright has over 25 years of experience in the biopharmaceutical industry. Ms. Bright joined the Company in November 2014 as Senior Vice President and Head of Europe and then served as Chief Commercial and Corporate Affairs Officer from February 2015 to July 2016. Prior to joining the Company, Ms. Bright worked at Gilead Sciences Ltd. starting in 2008, where she held positions of increasing responsibility, including: General Manager United Kingdom & Ireland; Vice President, Northern Europe; Vice President, Head of Sovaldi Launch Planning for Europe, Asia, Middle East and Australasia; and Vice President, Government Affairs Europe, Middle East and Australasia. Prior to holding these positions, Ms. Bright held a range of senior positions at GlaxoSmithKline plc, including Vice President and Managing Director of New Zealand and Vice President—Sales for the United Kingdom. Ms. Bright has been a director of Ascendis Pharma A/S since April 2017 and Dechra Pharmaceuticals PLC since February 2019. Ms. Bright has a B.Sc. in pharmacology from University College London.
As the President и International of Intercept Pharmaceuticals Inc, the total compensation of Lisa Bright at Intercept Pharmaceuticals Inc is $1,932,940. There are 6 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
Lisa Bright is 52, she's been the President и International of Intercept Pharmaceuticals Inc since 2016. There are 11 older and 9 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Lisa's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK, NY, 10001.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein и Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: